Ensartinib Hydrochloride

盐酸恩沙替尼

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameEnsartinib Hydrochloride
Drug Alias Name盐酸爱沙替尼Ensartinib盐酸恩莎替尼Ensartinibum恩莎替尼 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAnaplastic lymphoma kinase inhibitorsHepatocyte growth factor receptor inhibitorsProto-oncogene tyrosine-protein kinase ROS inhibitors
TargetsAnaplastic lymphoma kinaseHepatocyte growth factor receptorProto-oncogene tyrosine-protein kinase ROS
Therapy Area/IndicationsBrain metastasesSolid tumoursXanthogranuloma, Juvenile +[25] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2020/11/17
Country/TerritoryCzechiaBelgiumCanada +[21] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesXcovery
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesXcovery Holdings,IncXcoveryCatalent Pharma Solutions +[9] 
Inactive CompaniesLudwig Institute For Cancer Research
Active IndicationsBrain metastasesSolid tumoursXanthogranuloma, Juvenile +[23] 
Inactive IndicationsCarcinomaNeoplasms

Other Information

ATC CodeL01XE
Related LinksDrugBankKEGG